tweetindex
ES
EnglishEspañolItalianoDeutschBahasa IndonesiaPortuguêsРусскийFrançaisไทยTürkçe

FDA Oncology

@FDAOncology · Silver Spring, MD · joined 27 Feb 2017

FDA Oncology Center of Excellence expedites medical product development to improve the lives of people with cancer.

41 586Followers
350Following
8 826Posts total
14.4KViews on collected posts

Últimas publicaciones

FDA Oncology@FDAOncology
🚨 We're moving! To stay up to date on the latest news, announcements, and updates, follow us at @FDADrugs. This account will no longer be actively updated and will be deactivated on 9/12, so make the switch today—we'll see you there! https://t.co/zd27I4DSPp
The image is an announcement from the U.S. Food and Drug Administration (FDA) stating, "We're moving!" It directs users to follow FDA social media accounts on Facebook, Twitter, Instagram, and LinkedIn for updates. The bottom features an outline of an FDA building.
2.3K views · 7 likes · 3 reposts · 2 replies Open on X →
FDA Oncology@FDAOncology
NEWS: @US_FDA approves a treatment for prostate cancer. https://t.co/S8QXjcJSL2 https://t.co/azXLp1mGoj
2.2K views · 8 likes · 5 reposts · 1 replies Open on X →
FDA Oncology@FDAOncology
@FDAOncology You hade to stop this trial. The combination of Darzalex and Pepaxto was too good. https://t.co/SYcxZdTHNX Instead you kill elderly with Pomalyst, Lenalidomide and other IMiDs. You had to falsify p-values to not reveal it. How many elderly did you kill today? 35 views · 1 likes · 0 reposts · 0 replies Open on X →
FDA Oncology@FDAOncology
Fewer than 5% of cancer patients receiving treatment have the opportunity to participate in a clinical trial due to restrictions on who is eligible to participate. Today FDA is issuing guidance to broaden the criteria for participation. https://t.co/6EbZErbswT https://t.co/2jGvHZ
A promotional graphic from the U.S. Food and Drug Administration on a dark navy blue background. At the top, bold white text reads "FDA ANNOUNCES THREE" followed by a green banner with white text reading "FINAL GUIDANCES." Below that, white text states: "To help accelerate drug development by expanding eligibility criteria in cancer clinical trials." The center of the image features a large circular illustration in shades of green and blue, incorporating icons representing drug development and clinical research: colorful capsule pills, a laboratory flask, a DNA double helix, molecular structures, bar and line charts, a cancer awareness ribbon, and a row of human figures representing diverse trial participants. The FDA logo appears in a white box in the lower right corner.
5.3K views · 16 likes · 5 reposts · 1 replies Open on X →
FDA Oncology@FDAOncology
NEWS: @US_FDA approves a treatment for ROS1-positive non-small cell lung cancer. https://t.co/rqaSYMhe45 https://t.co/NadHPYcKzp
"An FDA-branded promotional image with a blue background. A person wearing a blue shirt holds up a white awareness ribbon — the symbol associated with lung cancer awareness. In the lower left, bold white and italic text reads: 'FDA approves a treatment for ROS1-positive non-small cell lung cancer.' The FDA logo appears in the upper left corner."
2.7K views · 21 likes · 9 reposts · 0 replies Open on X →
FDA Oncology@FDAOncology
July is #SarcomaAwarenessMonth! Sarcoma is a rare cancer affecting bones and soft tissues. CURE ID, an FDA & NIH platform, collects real-world treatment experiences for sarcomas and other rare diseases. Make a difference by sharing your experience at: https://t.co/2dfLV5RdRn http
"A promotional image with a dark blue background. On the left, bold white and cyan text reads 'Help advance research for rare sarcomas.' In the upper right corner are the logos for the FDA and NIH's National Center for Advancing Translational Sciences (NCATS). In the foreground, a female healthcare provider in a white coat and scrubs holds a tablet and smiles at a female patient who is lying in a hospital bed wearing a hospital gown and cap."
1.8K views · 5 likes · 3 reposts · 0 replies Open on X →

Frente a cuentas del mismo tamaño

6 publicaciones de los últimos 90 días, junto al rango de 10K–100K seguidores. llega a mucha gente, pero pocos de esos espectadores reaccionan.

Visualizaciones medianas2 243esta cuenta982mediana de 10K–100K
Alcance, %5.39%esta cuenta3.75%mediana de 10K–100K
Interacción, %0.58%esta cuenta1.52%mediana de 10K–100K
MétricaEsta cuentaMediana de 10K–100KProporción
Visualizaciones medianas por publicación2 2439822.28×
Alcance (visualizaciones ÷ seguidores)5.39%3.75%1.44×
Tasa de interacción0.58%1.52%0.38×

Otras cuentas de este rango →   Comparar con otra cuenta →   Cómo se construyen estas referencias →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

1.8K16 Jul
2.7K24 Jul
5.3K27 Jul
3531 Jul
2.2K
2.3K12 Aug

Last 6 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

0.45%16 Jul
1.10%24 Jul
0.41%27 Jul
2.86%31 Jul
0.64%
0.52%12 Aug

Reactions — likes, reposts, replies and quotes — divided by views. Median for 10K–100K accounts is 1.52%.

What the audience does

Likes61.1%58 in total
Reposts26.3%25 in total
Replies4.2%4 in total
Bookmarks8.4%8 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.

Cuentas similares

The FPL Bois ✓ @thefplbois 83.2K followers · 105.6K posts Koichi Nakano@Progressive! Channel @knakano1970 83.2K followers · 64.6K posts Mina Feliciangeli @minaftv 83.2K followers · 16.4K posts Martí Perarnau @martiperarnau 83.2K followers · 98.1K posts StationOfPlay @StationOfPlay 83.2K followers · 35.9K posts G Jones @gjonesbass 83.2K followers · 9.6K posts JLR @JLR_News 83.2K followers · 3.9K posts Ball Don't Stop ✓ @balldontstop 83.2K followers · 16.6K posts